Eli Lilly and Company stock trades at EUR 1043.40 with a plus 0.23 percent daily change

Eli Lilly and Company (ISIN US5324571083) was trading at EUR 1043.40 at Lang & Schwarz on September 30, 2026 at 1:13 p.m. CEST, plus 0.23 percent versus the prior close of EUR 1041.00. The company scheduled new obesity and diabetes data for the European Association for the Study of Diabetes meeting, including Phase 2 eloraTZP results later on September 30, 2026.

EASD data set the next checkpoint

According to Eli Lilly and Company in its September 15, 2026 release, the eloraTZP symposium was scheduled for September 30, 2026, from 4:30 to 5:30 p.m. CEST. The program also included Phase 3 retatrutide results and data on Mounjaro and Foundayo, expanding the evidence base behind Lilly's cardiometabolic portfolio.

The release says an earlier eloraTZP Phase 1 analysis produced 17.00 percent weight loss over 16 weeks with the combination, versus 10.00 percent with tirzepatide alone. The comparison is important because the next data point concerns a newer combination rather than an established commercial product.

Quarterly growth meets pricing pressure

Zacks reported that Lilly's second-quarter 2026 adjusted EPS reached USD 8.38, versus a USD 6.01 consensus estimate. Revenue rose 47.70 percent year over year to USD 22.97 billion, while net realized prices declined 13.00 percent and volumes increased 60.00 percent.

The same report said Mounjaro generated USD 9.94 billion in second-quarter sales, up 91.00 percent year over year, while Zepbound sales reached USD 4.93 billion, up 46.00 percent. That mix shows why demand remains powerful, but the price and volume split makes execution and reimbursement central to the outlook.

JPMorgan raises its target

MarketBeat reported on September 28, 2026, that JPMorgan raised its Eli Lilly price target from USD 1,400.00 to USD 1,500.00 and maintained an overweight rating. The article also placed the average analyst target at USD 1,311.96 and cited pricing pressure and slower oral GLP-1 rollout as counter-factors.

Euro quote and prior close

Eli Lilly and Company was trading at EUR 1043.40 at Lang & Schwarz on September 30, 2026 at 1:13 p.m. CEST, plus 0.23 percent versus the Lang & Schwarz prior close of EUR 1041.00. The primary exchange is the NYSE, where the finance quote showed a market capitalization of USD 1.1 trillion and a 52-week range of USD 725.31 to USD 1292.65 as of September 29, 2026.

More news and analyses on Eli Lilly and Company stock